Showing 6071-6080 of 9076 results for "".
- Long-Term Baricitinib Data Reinforce Potential in Adolescents With AAhttps://practicaldermatology.com/news/long-term-baricitinib-data-reinforce-potential-in-adolescents-with-aa/2484088/More than half of adolescents treated for alopecia areata (AA) with baricitinib 4mg achieved successful scalp hair response by Week 52, with a response rate reaching 71% among those with baseline Severity of Alopecia Tool (SALT) score of 50-94, according to new data presented at the 2025 Fall Cli
- Dr. Woolery-Lloyd Appointed Program Development Advisor for Skin of Color Updatehttps://practicaldermatology.com/news/dr-woolery-lloyd-appointed-program-development-advisor-for-skin-of-color-update/2484015/Heather Woolery-Lloyd, MD, FAAD, has been appointed program development advisor for Skin of Color Update, the nation’s largest medical education event focused on dermatologic care for patients with skin of color. Dr. Woolery-Lloyd serves as director of the Skin of Color Division at the Uni
- Lower Neighborhood SES Linked to Increased HS Severity at Diagnosis: Analysishttps://practicaldermatology.com/news/lower-neighborhood-ses-linked-to-increased-hidradenitis-suppurativa-severity-at-diagnosis/2483997/New research suggests that lower neighborhood socioeconomic status (nSES) was associated with more severe hidradenitis suppurativa (HS) at the time of diagnosis. The recent cross-sectional analysis of 462 patients newly diagno
- Analysis: Long-Term Ixekizumab Not Linked to Higher Cancer Risk in PsO, PsAhttps://practicaldermatology.com/news/analysis-long-term-ixekizumab-not-linked-to-higher-cancer-risk-in-pso-psa/2483983/A recent pooled analysis of 25 randomized clinical trials (RCTs) found no increased risk of malignant neoplasms with long-term ixekizumab (IXE) therapy in patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA).
- Global CME Conference to Spotlight Eczema Burden, Treatment Advanceshttps://practicaldermatology.com/news/global-cme-conference-to-spotlight-eczema-burden-treatment-advances/2483912/Health & Wellness Global Alliance will host its inaugural H&W Global Dermatology CME Conference November 12-16, 2025, aiming to spotlight the international burden of eczematous diseases. The event aligns with the mission
- Pfizer and GWU Renew Grant Program to Expand Teledermatology Access for Inflammatory Skin Conditionshttps://practicaldermatology.com/news/pfizer-and-gwu-renew-grant-program-to-expand-teledermatology-access-for-inflammatory-skin-conditions/2483889/Pfizer Global Medical Grants and The George Washington University (GWU) have renewed their joint grant program focused on broadening access to dermatologic care in underserved U.S. communities. According to a GWU press announc
- Dr. Jennifer Soung: Ask Patient’s Permission Before Talking GLP-1shttps://practicaldermatology.com/news/dr-jennifer-soung-ask-patients-permission-before-talking-glp-1s/2483863/GLP-1 treatments have become commonplace in dermatology practices, with both aesthetic and medical dermatology implications heavily involved. Talking to patients about the latter issue, however, can prove challenging. Despite the mounting literature indicating that GLP-1 agonists can help allevia
- Roflumilast 0.05% Gains FDA Approval for Children 2-5 with ADhttps://practicaldermatology.com/news/roflumilast-005-gains-fda-approval-for-children-2-5-with-ad/2483862/The US Food and Drug Administration (FDA) has approved roflumilast cream 0.05% (Zoryve®, Arcutis Biotherapeutics) for the treatment of mild-to-moderate atopic dermatitis (AD) in children 2 to 5 years old. This once-daily topical phosphodiesterase-4 (PDE4) inhibitor
- FDA Approves Guselkumab for Children 6 and Older With PsOhttps://practicaldermatology.com/news/fda-approves-guselkumab-for-children-6-and-older-with-pso/2483604/The US Food and Drug Administration (FDA) has approved guselkumab (Tremfya®, Johnson & Johnson) for the treatment of children 6 and older, weighing at least 40 kg, with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA), making it the
- LEO Pharma Finalizes Acquisition of Spevigo® for Rare Dermatologic Diseaseshttps://practicaldermatology.com/news/leo-pharma-finalizes-acquisition-of-spevigo-for-rare-dermatologic-diseases/2483600/LEO Pharma has officially completed its acquisition of Spevigo® (spesolimab) from Boehringer Ingelheim, according to a press release from the manufacturer. The purchase represents the c